Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease

Fexi anti‐protozoal activity against T. cruzi has been demonstrated by various in vitro and in vivo studies. Patients will be randomly assigned to receive one of three different treatment regimen arms containing either the active drug or matching placebo tablet Following conclusion of 12 months of follow‐up of DNDi‐CH‐FEXI‐001 clinical trial, unblinded data review showed high sustained parasite clearance rates of FEXI even at the lowest dose tested (1200 mg 2 weeks), including in patients that received < 3days treatment.